[email protected] @ISRREPORTS ISRREPORTS.COM BRAIN CANCER BRAIN CANCER profile & drug Development Glioblastoma Multiforme (GBM) GBM is slightly more common in males and slightly more common in Caucasians (in US). Rapid tumor growth, highly resistant tumors, and a lack of effective therapies contribute to making this one of the deadliest cancer types. GBM is classified as an This is defined as a disease that affects fewer than 200,000 people (in the U.S.). 58 PHARMA & biotech companies have sponsored GBM trials since 2010. 50 potential new therapies in active development, positive results in early stage trials. These new therapies include: • Immunotherapeutic Vaccines • Anti-Angiogenesis • Gene Therapy • Cell Signaling Pathway Inhibitors • Cytotoxics What is GBM? what is GBM? treatment treatment the future The future www.ISRreports.com GBM is the most common and most aggressive form of primary malignant brain tumor. • Seizures • Nausea and vomiting • Headaches • Hemiparesis • Memory, personality, or neurological deficits symptoms 240,000 people are diagnosed with GBM globally each year. That’s equivalent to the population of Durham, NC. that’s 2-3 cases per 100,000 adults Breast Cancer: 89% Colorectal: 64% Glioblastoma: 4.8% Lung: 15% Prostate: 99% 5 y e a r S u r v i v a l R a t e No available treatment for GBM is curative and options are extremely limited. The most optimal treatment for GBM is a combination of surgery, radiotherapy, and chemotherapy. Without treatment, the mean life expectancy is approximately 4.5 months. With standard of care treatment the average life expectancy rises to approximately 15 months. Potential therapies can be eligible for Orphan Drug Designation, which allows the developing company to receive tax breaks and market exclusivity upon approval of the therapy. 76 GBM clinical trials were started in 2013 Sources: ISR Reports, brain.mgh.harvard.edu, cancer.org, http://visual.ly/brain-cancer-infographic, www.mdanderson.org, seer.cancer.gov, International Agency for Research on Cancer Scientific Publications Number 155, 2002, www.cbtrus.org, http://globocan.iarc.fr, neurosurgery.ucsd.edu/glioblastoma/, emedi- cine.medspace.com, GOAL: removes as much tumor tissue as possible. It is believed that surgery gives patients a better prognosis when they begin other treatment. 1. Radiation aims to kill as many of the cells left behind from surgery as possible . 2. Radiation is usually given 5 times a week for 6 weeks. 3. Radiation is combined with the oral chemotherapy, Temozolomide. GOAL: Chemotherapy and radiation aim to put the remaining cancer cells into a nondividing, sleeping state. surgery radiation chemotherapy Temozolomide increases survival time from 12.1 months to 14.6 months. 25% of patients benefit from adjuvant chemotherapy.

Brain Cancer (Glioblastoma Multiforme): Profile & Drug Development

Download PDF Report

Upload
industry-standard-research
View
571
Download
2

Embed Size (px)

DESCRIPTION

GBM is the most common and most aggressive form of primary malignant brain tumor. This infographic from ISR explores the disease, treatment, and possibilities for the future.

Citation preview

[email protected] @ISRREPORTS ISRREPORTS.COM

BRAIN CANCERBRAIN CANCER

profile & drug

Development

Glioblastoma

Multiforme

(GBM)

GBM is slightly more common in

males and slightly more common in

Caucasians (in US).

Rapid tumor growth, highly resistant tumors, and a lack of e�ective therapies contribute to making this one of

the deadliest cancer types.

GBM is classified as an

This is defined as a disease that a�ects fewer than 200,000 people (in the U.S.).

58 PHARMA & biotech companies have sponsored GBM trials since 2010.

50 potential new therapies in active development, positive results in early stage trials.

These new therapies include:• Immunotherapeutic Vaccines• Anti-Angiogenesis• Gene Therapy• Cell Signaling Pathway Inhibitors• Cytotoxics

What is GBM?what is GBM?

treatmenttreatment

the futureThe future

www.ISRreports.com

GBM is the most common and most aggressive form of primary malignant brain tumor.

• Seizures• Nausea and vomiting• Headaches• Hemiparesis• Memory, personality, or neurological deficits

symptoms

240,000 people are diagnosed with GBM globally each year. That’s

equivalent to the population of Durham, NC.

that’s2-3 cases

per 100,000

adults

Breast Cancer: 89%Colorectal: 64%

Glioblastoma: 4.8%Lung: 15%

Prostate: 99%

5 y

ear Survival R

ate

No available treatment for GBM is curative and options are extremely limited.

The most optimal treatment for GBM is a combination of surgery, radiotherapy, and chemotherapy.

Without treatment, the mean life expectancy is approximately

4.5 months.

With standard of care treatment the average life expectancy rises to approximately

15 months.

Potential therapies can be eligible for Orphan Drug Designation, which allows the developing company to receive tax breaks and market exclusivity upon approval of the therapy.

76 GBM clinical trials were started in 2013

Sources: ISR Reports, brain.mgh.harvard.edu, cancer.org, http://visual.ly/brain-cancer-info-graphic, www.mdanderson.org, seer.can-cer.gov, International Agency for Research on Cancer Scientific Publications Number 155, 2002, www.cbtrus.org, http://globocan.iarc.fr, neurosurgery.ucsd.edu/glioblastoma/, emedi-cine.medspace.com,

GOAL: removes as much tumor tissue as possible. It is believed that surgery gives patients a better prognosis when they begin other treatment.

1. Radiation aims to kill as many of the cells left behind from surgery as possible .2. Radiation is usually given 5 times a week for 6 weeks.3. Radiation is combined with the oral chemotherapy, Temozolomide.

GOAL: Chemotherapy and radiation aim to put the remaining cancer cells into a nondividing, sleeping state.

surgery

radiation

chemotherapy

Temozolomide increases survival

time from

12.1 months to

14.6 months.

25% of patients benefit from adjuvant chemotherapy.